Spray Drying

Symeres provides integrated spray drying services to support formulation development for poorly soluble and development-challenged small molecule drug candidates.

As part of our broader Chemistry, Manufacturing, and Controls (CMC) platform, spray drying is integrated with formulation sciences, analytical characterization, solid-state chemistry, and process development to help accelerate drug development from preclinical studies through Phase III clinical trials.

Our multidisciplinary scientific teams work together within a single CMC development environment, enabling closer collaboration, efficient decision-making, and streamlined progression throughout the drug development journey. By integrating spray drying within our broader CMC platform, Symeres provides a single-source solution spanning formulation development, analytical characterization, process development, enabling technologies, and clinical-phase manufacturing. This integrated approach helps reduce operational complexity, minimize technology transfer risk, and support confident progression from formulation feasibility through clinical development.

Capabilities include:

Amorphous solid dispersion (ASD) development – Support bioavailability enhancement and solubility optimization for poorly soluble small molecule drug candidates.
Laboratory- and pilot-scale spray drying – Support rapid material screening, formulation feasibility studies, process optimization, and scalable process development from early formulation screening through clinical-ready material.
Particle engineering – Optimize particle characteristics to support formulation development and improve product performance.
Integrated analytical characterization – Support spray drying programs through the evaluation of particle morphology, particle size distribution, crystallinity, dissolution behavior, physical stability, and residual solvent control.
Process development and technology transfer – Develop scalable spray drying processes that support efficient progression toward clinical development.
Integrated formulation sciences – Combine formulation development, analytical characterization, solid-state chemistry, spray drying, process development and stability within a coordinated CMC framework to improve development continuity and reduce operational complexity.

Frequently Asked Questions

What spray drying services does Symeres offer?

Symeres provides laboratory- and pilot-scale spray drying services to support formulation development for poorly soluble small molecule drug candidates. Our capabilities include amorphous solid dispersion (ASD) development, process optimization, analytical characterization, scalable process development, stability and technology transfer as part of our integrated CMC offering.

When is spray drying used during drug development?

Spray drying is commonly used when small molecule drug candidates have poor aqueous solubility or require bioavailability enhancement. It supports formulation development by enabling advanced approaches such as amorphous solid dispersions and particle engineering.

What are amorphous solid dispersions (ASDs)?

Amorphous solid dispersions (ASDs) are advanced materials designed to improve the performance of poorly soluble drug candidates. Spray drying is one of the most widely used technologies for producing ASDs during pharmaceutical development.

Which compounds benefit most from spray drying?

Spray drying is particularly valuable for Biopharmaceutics Classification System (BCS) Class II and IV compounds, highly lipophilic molecules, and other development-challenged small molecule drug candidates that require bioavailability enhancement or solubility optimization.

Does Symeres provide analytical support alongside spray drying?

Yes. Spray drying programs are supported by integrated analytical characterization and solid-state expertise. Our scientists evaluate particle morphology, crystallinity, dissolution behavior, physical stability, and residual solvent control to support informed formulation development.

Can Symeres support spray drying through Phase II?

Yes. Symeres supports early formulation feasibility studies, IND-enabling development, preformulation, clinical trial material support, process optimization, technology transfer, and scalable process development through Phase III clinical studies.

Why choose Symeres as a spray drying partner?

Unlike standalone spray drying providers, Symeres integrates spray drying with API supply, form selection, formulation sciences, analytical characterization, solid-state chemistry, and process development within a single CMC environment. This coordinated approach reduces technology transfer risk, streamlines development activities, maintains scientific continuity, and enables efficient progression from formulation feasibility through clinical development.

Related services

Formulation and analytical development

Solid state chemistry

Process development

GMP manufacturing

GMP starting materials

Your transatlantic drug development partner

Symeres support small-molecule programs from discovery through IND with openness, agility and scientific depth. Our connected teams in Europe and North America provide medicinal chemistry, computational chemistry, synthetic chemistry, and specialty chemistry services integrated with biology, ADME-tox, and CMC development.

We share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous. Projects can run as standalone studies or as coordinated, multi-disciplinary programs

Integrated technologies for smarter drug development

Our (pre)clinical drug development and CMC services are closely aligned with our discovery platforms. In vitro ADME-tox, pharmacology, and solid-state chemistry are aligned to our process development and manufacturing capabilities.

This approach removes handoffs that could compromise your budget and timelines and supports regulatory filings to provide a clear path from discovery to IND.

Learn about our quality

Delivered through Exemplify

This service offering is delivered through Exemplify BioPharma, a Symeres company.

Exemplify BioPharma provides integrated CMC development expertise, supporting small molecule programmes across process chemistry, analytical development, solid-state chemistry, formulation development and clinical trial material manufacturing.

Resources we think you'll love

Webinar | On-demand

What Large Cell Panel Profiling Reveals About Your ADC

Explore how large cell panel profiling and bioinformatics analysis can provide deeper insight into antibody-drug conjugate (ADC) activity, selectivity and response. This on-demand webinar examines how these approaches can help identify predictive response markers, support patient selection, confirm mechanism of action and generate hypotheses around potential resistance mechanisms.

Spray Drying

Capabilities include:

Frequently Asked Questions

Related services

Your transatlantic drug development partner

Integrated technologies for smarter drug development

Delivered through Exemplify

Resources we think you'll love

What Large Cell Panel Profiling Reveals About Your ADC

DILI uncovered: from animal models to a weight-of-evidence future

Your Questions, Answered: Hit Discovery, Hard Choices, and the SymeGold Library

DILI Uncovered: how to mitigate hepatoxicity failure

The Greatest Hits: A beginner’s guide to high-quality starting points for Drug Discovery

ADME-Tox testing in drug discovery: your questions answered

Embracing scientific complexity to mitigate toxicity issues and development risks while advancing toward the clinic

Map your molecule’s next move with the Symeres developability roadmap

Three Signs Your Synthetic Route Will Collapse at Scale

Lead optimization: what data actually drive decisions?

When slowing chemistry speeds programs up

When a clean PK profile is actually a warning sign

CDMO red flags you can’t ignore: Communication breakdowns

CDMO red flags you can’t ignore: Capacity constraints and resource stretch

CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment

5 CDMO red flags you can’t ignore: A guide for biotechs and pharma

CDMO red flags you can’t ignore: Underestimating technology transfer complexity

O.N.E Symeres: A practical approach to real-world drug development

CDMO red flags you can’t ignore: Undefined or shifting project scope

Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry

From racemic to pure the art and science of enantiomer separation

IND & IMPD enabling developability roadmap

Innovations in unnatural amino acids: Advancing functional diversity and applications

Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D

Managing nitrosamines in the pharmaceutical industry: A comprehensive approach

Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction

Stable isotope-labeled compounds

Unlocking the potential of high-throughput screening: Symegold library design and expansion insights

Insights into drug discovery and development 2025

Interview with the computer-aided drug design (CADD) department

Meet the Organix Director, Mario Gonzalez

Interview with the new Managing Director of Symeres Groningen

An interview with Yadan Chen and Paul O’Shea

An interview with Anu Mahadevan and Paul Blundell

Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

In vivo pharmacokinetic experiments in preclinical drug development

Accelerating medicinal chemistry by rapid analoging

Solid-state chemistry part II: Optimal form selection by controlled crystallization

Route scouting for kilogram-scale manufacturing of APIs

Solid-state chemistry part I: Introduction